Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 49 to 59 of 59 entries
Sorted by: Best Match Show Resources per page
New hepatitis B vaccine schedule for children with celiac disease.

Hepatitis monthly

Leonardi S, Miraglia Del Giudice M, La Rosa M.
PMID: 22224087
Hepat Mon. 2011 Oct;11(10):850-1. doi: 10.5812/kowsar.1735143x.772.

No abstract available.

Cite
Leonardi S, Miraglia Del Giudice M, La Rosa M. New hepatitis B vaccine schedule for children with celiac disease. Hepat Mon. 2011;11(10):850-1doi: 10.5812/kowsar.1735143x.772.
Leonardi, S., Miraglia Del Giudice, M., & La Rosa, M. (2011). New hepatitis B vaccine schedule for children with celiac disease. Hepatitis monthly, 11(10), 850-1. https://doi.org/10.5812/kowsar.1735143x.772
Leonardi, Salvatore, et al. "New hepatitis B vaccine schedule for children with celiac disease." Hepatitis monthly vol. 11,10 (2011): 850-1. doi: https://doi.org/10.5812/kowsar.1735143x.772
Leonardi S, Miraglia Del Giudice M, La Rosa M. New hepatitis B vaccine schedule for children with celiac disease. Hepat Mon. 2011 Oct;11(10):850-1. doi: 10.5812/kowsar.1735143x.772. PMID: 22224087; PMCID: PMC3234571.
Copy Download .nbib Format: NLM
Immune response to hepatitis B vaccine in patients with chronic kidney disease.

Hepatitis monthly

Einollahi B.
PMID: 22224074
Hepat Mon. 2011 Oct;11(10):781-2. doi: 10.5812/kowsar.1735143x.766.

No abstract available.

Cite
Einollahi B. Immune response to hepatitis B vaccine in patients with chronic kidney disease. Hepat Mon. 2011;11(10):781-2doi: 10.5812/kowsar.1735143x.766.
Einollahi, B. (2011). Immune response to hepatitis B vaccine in patients with chronic kidney disease. Hepatitis monthly, 11(10), 781-2. https://doi.org/10.5812/kowsar.1735143x.766
Einollahi, Behzad. "Immune response to hepatitis B vaccine in patients with chronic kidney disease." Hepatitis monthly vol. 11,10 (2011): 781-2. doi: https://doi.org/10.5812/kowsar.1735143x.766
Einollahi B. Immune response to hepatitis B vaccine in patients with chronic kidney disease. Hepat Mon. 2011 Oct;11(10):781-2. doi: 10.5812/kowsar.1735143x.766. PMID: 22224074; PMCID: PMC3234580.
Copy Download .nbib Format: NLM
Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience.

Pediatric gastroenterology, hepatology & nutrition

Lu FT, Ni YH, Evett SR, Kustas WP, Gowda PH, Anderson MC.
PMID: 32704492
Pediatr Gastroenterol Hepatol Nutr. 2020 Jul;23(4):311-318. doi: 10.5223/pghn.2020.23.4.311. Epub 2020 Jul 03.

Chronic hepatitis B viral (HBV) infection remains a major health threat, especially in high-prevalence areas. Most infants infected by mother-to-infant HBV transmission become chronic carriers. In Taiwan, many important preventive interventions have been implemented to block the perinatal transmission...

Cite
Lu FT, Ni YH, Evett SR, et al. Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience. Pediatr Gastroenterol Hepatol Nutr. 2020;23(4):311-318doi: 10.5223/pghn.2020.23.4.311.
Lu, F. T., Ni, Y. H., Evett, S. R., Kustas, W. P., Gowda, P. H., & Anderson, M. C. (2020). Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience. Pediatric gastroenterology, hepatology & nutrition, 23(4), 311-318. https://doi.org/10.5223/pghn.2020.23.4.311
Lu, Fang-Ting, et al. "Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience." Pediatric gastroenterology, hepatology & nutrition vol. 23,4 (2020): 311-318. doi: https://doi.org/10.5223/pghn.2020.23.4.311
Lu FT, Ni YH, Evett SR, Kustas WP, Gowda PH, Anderson MC. Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience. Pediatr Gastroenterol Hepatol Nutr. 2020 Jul;23(4):311-318. doi: 10.5223/pghn.2020.23.4.311. Epub 2020 Jul 03. PMID: 32704492; PMCID: PMC7354867.
Copy Download .nbib Format: NLM
The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route.

Immunity & ageing : I & A

Edelman R, Deming ME, Toapanta FR, Heuser MD, Chrisley L, Barnes RS, Wasserman SS, Blackwelder WC, Handwerger BS, Pasetti M, Siddiqui KM, Sztein MB.
PMID: 32355503
Immun Ageing. 2020 Apr 28;17:9. doi: 10.1186/s12979-020-00179-9. eCollection 2020.

BACKGROUND: Reduced response to hepatitis B vaccines is associated with aging, confounding and comorbid conditions, as well as inadvertent subcutaneous (SC) inoculation. We hypothesized that the antibody and T cell-mediated immune responses (T-CMI) of elderly adults to a vaccine...

Cite
Edelman R, Deming ME, Toapanta FR, et al. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immun Ageing. 2020;17:9doi: 10.1186/s12979-020-00179-9.
Edelman, R., Deming, M. E., Toapanta, F. R., Heuser, M. D., Chrisley, L., Barnes, R. S., Wasserman, S. S., Blackwelder, W. C., Handwerger, B. S., Pasetti, M., Siddiqui, K. M., & Sztein, M. B. (2020). The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immunity & ageing : I & A, 179. https://doi.org/10.1186/s12979-020-00179-9
Edelman, Robert, et al. "The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route." Immunity & ageing : I & A vol. 17 (2020): 9. doi: https://doi.org/10.1186/s12979-020-00179-9
Edelman R, Deming ME, Toapanta FR, Heuser MD, Chrisley L, Barnes RS, Wasserman SS, Blackwelder WC, Handwerger BS, Pasetti M, Siddiqui KM, Sztein MB. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immun Ageing. 2020 Apr 28;17:9. doi: 10.1186/s12979-020-00179-9. eCollection 2020. PMID: 32355503; PMCID: PMC7187507.
Copy Download .nbib Format: NLM
Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study.

Interdisciplinary toxicology

Geier DA, Kern JK, Hooker BS, King PG, Sykes LK, Homme KG, Geier MR.
PMID: 27486363
Interdiscip Toxicol. 2015 Jun;8(2):68-76. doi: 10.1515/intox-2015-0011.

A hypothesis testing, case-control study evaluated automated medical records for exposure to organic-Hg from Thimerosal-containing hepatitis B vaccines (TM-HepB) administered at specific intervals in the first six-months-of-life among cases diagnosed with a tic disorder (TD) or cerebral degeneration (CD)...

Cite
Geier DA, Kern JK, Hooker BS, et al. Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study. Interdiscip Toxicol. 2015;8(2):68-76doi: 10.1515/intox-2015-0011.
Geier, D. A., Kern, J. K., Hooker, B. S., King, P. G., Sykes, L. K., Homme, K. G., & Geier, M. R. (2015). Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study. Interdisciplinary toxicology, 8(2), 68-76. https://doi.org/10.1515/intox-2015-0011
Geier, David A, et al. "Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study." Interdisciplinary toxicology vol. 8,2 (2015): 68-76. doi: https://doi.org/10.1515/intox-2015-0011
Geier DA, Kern JK, Hooker BS, King PG, Sykes LK, Homme KG, Geier MR. Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study. Interdiscip Toxicol. 2015 Jun;8(2):68-76. doi: 10.1515/intox-2015-0011. PMID: 27486363; PMCID: PMC4961900.
Copy Download .nbib Format: NLM
Population-based interventions to reduce the public health burden related with hepatitis B virus infection in the gambia, west Africa.

Tropical medicine and health

Shimakawa Y, Lemoine M, Mendy M, Njai HF, D'Alessandro U, Hall A, Thursz M, Njie R.
PMID: 25425952
Trop Med Health. 2014 Jun;42(2):59-64. doi: 10.2149/tmh.2014-S08.

In The Gambia, West Africa, the prevalence of chronic hepatitis B virus (HBV) infection in adults exceeds eight percent and hepatocellular carcinoma (HCC) has been the most frequent type of malignancy. Two population-based intervention studies to control HBV infection,...

Cite
Shimakawa Y, Lemoine M, Mendy M, et al. Population-based interventions to reduce the public health burden related with hepatitis B virus infection in the gambia, west Africa. Trop Med Health. 2014;42(2):59-64doi: 10.2149/tmh.2014-S08.
Shimakawa, Y., Lemoine, M., Mendy, M., Njai, H. F., D'Alessandro, U., Hall, A., Thursz, M., & Njie, R. (2014). Population-based interventions to reduce the public health burden related with hepatitis B virus infection in the gambia, west Africa. Tropical medicine and health, 42(2), 59-64. https://doi.org/10.2149/tmh.2014-S08
Shimakawa, Yusuke, et al. "Population-based interventions to reduce the public health burden related with hepatitis B virus infection in the gambia, west Africa." Tropical medicine and health vol. 42,2 (2014): 59-64. doi: https://doi.org/10.2149/tmh.2014-S08
Shimakawa Y, Lemoine M, Mendy M, Njai HF, D'Alessandro U, Hall A, Thursz M, Njie R. Population-based interventions to reduce the public health burden related with hepatitis B virus infection in the gambia, west Africa. Trop Med Health. 2014 Jun;42(2):59-64. doi: 10.2149/tmh.2014-S08. PMID: 25425952; PMCID: PMC4204052.
Copy Download .nbib Format: NLM
[Safety evaluation of 10 μg recombinant hepatitis B vaccine (.

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Zeng Y, Zhang JK, Tang Y, Yang ZH, Su JL, Chen LY, Huang ZH, Zeng PY, Jian ZY, Du WM, Yang MW, Wang TT, Wang FZ, Liang XF, Zheng HZ.
PMID: 29262496
Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Dec 06;51(12):1121-1123. doi: 10.3760/cma.j.issn.0253-9624.2017.12.014.

No abstract available.

Cite
Zeng Y, Zhang JK, Tang Y, et al. [Safety evaluation of 10 μg recombinant hepatitis B vaccine (. Zhonghua Yu Fang Yi Xue Za Zhi. 2017;51(12):1121-1123doi: 10.3760/cma.j.issn.0253-9624.2017.12.014.
Zeng, Y., Zhang, J. K., Tang, Y., Yang, Z. H., Su, J. L., Chen, L. Y., Huang, Z. H., Zeng, P. Y., Jian, Z. Y., Du, W. M., Yang, M. W., Wang, T. T., Wang, F. Z., Liang, X. F., & Zheng, H. Z. (2017). [Safety evaluation of 10 μg recombinant hepatitis B vaccine (. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 51(12), 1121-1123. https://doi.org/10.3760/cma.j.issn.0253-9624.2017.12.014
Zeng, Y, et al. "[Safety evaluation of 10 μg recombinant hepatitis B vaccine (." Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] vol. 51,12 (2017): 1121-1123. doi: https://doi.org/10.3760/cma.j.issn.0253-9624.2017.12.014
Zeng Y, Zhang JK, Tang Y, Yang ZH, Su JL, Chen LY, Huang ZH, Zeng PY, Jian ZY, Du WM, Yang MW, Wang TT, Wang FZ, Liang XF, Zheng HZ. [Safety evaluation of 10 μg recombinant hepatitis B vaccine (. Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Dec 06;51(12):1121-1123. doi: 10.3760/cma.j.issn.0253-9624.2017.12.014. Chinese. PMID: 29262496.
Copy Download .nbib Format: NLM
Serum albumin level as an indicator of response to Hepatitis B vaccination in dialysis patients: A systematic review and meta-analysis.

Caspian journal of internal medicine

Ghamar-Chehreh ME, Agah S, Khedmat H, Aghaei A, Alavian SM.
PMID: 29201314
Caspian J Intern Med. 2017;8(4):250-257. doi: 10.22088/cjim.8.4.250.

BACKGROUND: Hepatitis B (HB) vaccination is a recommended procedure in all dialysis patients, but its efficacy has not been perfect. In the current study, we aimed to conduct a comprehensive review of the literature to find and pool data...

Cite
Ghamar-Chehreh ME, Agah S, Khedmat H, et al. Serum albumin level as an indicator of response to Hepatitis B vaccination in dialysis patients: A systematic review and meta-analysis. Caspian J Intern Med. 2017;8(4):250-257doi: 10.22088/cjim.8.4.250.
Ghamar-Chehreh, M. E., Agah, S., Khedmat, H., Aghaei, A., & Alavian, S. M. (2017). Serum albumin level as an indicator of response to Hepatitis B vaccination in dialysis patients: A systematic review and meta-analysis. Caspian journal of internal medicine, 8(4), 250-257. https://doi.org/10.22088/cjim.8.4.250
Ghamar-Chehreh, Mohammad Ebrahim, et al. "Serum albumin level as an indicator of response to Hepatitis B vaccination in dialysis patients: A systematic review and meta-analysis." Caspian journal of internal medicine vol. 8,4 (2017): 250-257. doi: https://doi.org/10.22088/cjim.8.4.250
Ghamar-Chehreh ME, Agah S, Khedmat H, Aghaei A, Alavian SM. Serum albumin level as an indicator of response to Hepatitis B vaccination in dialysis patients: A systematic review and meta-analysis. Caspian J Intern Med. 2017;8(4):250-257. doi: 10.22088/cjim.8.4.250. PMID: 29201314; PMCID: PMC5686302.
Copy Download .nbib Format: NLM
12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial.

Vaccines

Han B, Liu W, Du J, Liu H, Zhao T, Yang S, Wang S, Zhang S, Liu B, Liu Y, Cui F.
PMID: 34960153
Vaccines (Basel). 2021 Nov 29;9(12). doi: 10.3390/vaccines9121407.

BACKGROUND: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China.METHODS: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to...

Cite
Han B, Liu W, Du J, et al. 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines (Basel). 2021;9(12)doi: 10.3390/vaccines9121407.
Han, B., Liu, W., Du, J., Liu, H., Zhao, T., Yang, S., Wang, S., Zhang, S., Liu, B., Liu, Y., & Cui, F. (2021). 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines, 9(12), . https://doi.org/10.3390/vaccines9121407
Han, Bingfeng, et al. "12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial." Vaccines vol. 9,12 (2021). doi: https://doi.org/10.3390/vaccines9121407
Han B, Liu W, Du J, Liu H, Zhao T, Yang S, Wang S, Zhang S, Liu B, Liu Y, Cui F. 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines (Basel). 2021 Nov 29;9(12). doi: 10.3390/vaccines9121407. PMID: 34960153.
Copy Download .nbib Format: NLM
Hepatitis B Vaccines.

The Journal of infectious diseases

Pattyn J, Hendrickx G, Vorsters A, Van Damme P.
PMID: 34590138
J Infect Dis. 2021 Sep 30;224(12):S343-S351. doi: 10.1093/infdis/jiaa668.

Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality. Affordable,...

Cite
Pattyn J, Hendrickx G, Vorsters A, et al. Hepatitis B Vaccines. J Infect Dis. 2021;224(12):S343-S351doi: 10.1093/infdis/jiaa668.
Pattyn, J., Hendrickx, G., Vorsters, A., & Van Damme, P. (2021). Hepatitis B Vaccines. The Journal of infectious diseases, 224(12), S343-S351. https://doi.org/10.1093/infdis/jiaa668
Pattyn, Jade, et al. "Hepatitis B Vaccines." The Journal of infectious diseases vol. 224,12 (2021): S343-S351. doi: https://doi.org/10.1093/infdis/jiaa668
Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B Vaccines. J Infect Dis. 2021 Sep 30;224(12):S343-S351. doi: 10.1093/infdis/jiaa668. PMID: 34590138; PMCID: PMC8482019.
Copy Download .nbib Format: NLM
Vaccinations and inflammatory bowel disease - a systematic review.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Chan W, Salazar E, Lim TG, Ong WC, Shim HH.
PMID: 33994128
Dig Liver Dis. 2021 Sep;53(9):1079-1088. doi: 10.1016/j.dld.2021.04.015. Epub 2021 May 11.

INTRODUCTION: Patients with inflammatory bowel disease(IBD) are at risk of infections, many of which are preventable with vaccinations. We performed a systematic review on various aspects of vaccination in IBD.METHODS: We searched PubMed, and EMBASE databases, through 31 January...

Cite
Chan W, Salazar E, Lim TG, et al. Vaccinations and inflammatory bowel disease - a systematic review. Dig Liver Dis. 2021;53(9):1079-1088doi: 10.1016/j.dld.2021.04.015.
Chan, W., Salazar, E., Lim, T. G., Ong, W. C., & Shim, H. H. (2021). Vaccinations and inflammatory bowel disease - a systematic review. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53(9), 1079-1088. https://doi.org/10.1016/j.dld.2021.04.015
Chan, Webber, et al. "Vaccinations and inflammatory bowel disease - a systematic review." Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver vol. 53,9 (2021): 1079-1088. doi: https://doi.org/10.1016/j.dld.2021.04.015
Chan W, Salazar E, Lim TG, Ong WC, Shim HH. Vaccinations and inflammatory bowel disease - a systematic review. Dig Liver Dis. 2021 Sep;53(9):1079-1088. doi: 10.1016/j.dld.2021.04.015. Epub 2021 May 11. PMID: 33994128.
Copy Download .nbib Format: NLM
Showing 49 to 59 of 59 entries